{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:18:44Z","timestamp":1790248724451,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.leukres.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T23:18:11Z","timestamp":1483658291000},"page":"73-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Pegylated interferon alpha \u2013 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial"],"prefix":"10.1016","volume":"54","author":[{"given":"K.","family":"Gowin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kosiorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Tibes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Camoriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.leukres.2017.01.006_bib0005","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2017.01.006_bib0010","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2017.01.006_bib0015","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"17","key":"10.1016\/j.leukres.2017.01.006_bib0020","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"7037","key":"10.1016\/j.leukres.2017.01.006_bib0025","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"9464","key":"10.1016\/j.leukres.2017.01.006_bib0030","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2017.01.006_bib0035","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/asheducation-2013.1.529","article-title":"JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside","volume":"2013","author":"Gotlib","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"9","key":"10.1016\/j.leukres.2017.01.006_bib0040","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2017.01.006_bib0045","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8617","key":"10.1016\/j.leukres.2017.01.006_bib0050","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S0140-6736(88)92625-6","article-title":"Treatment of essential thrombocythaemia by alpha 2a interferon","volume":"2","author":"Bellucci","year":"1988","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.leukres.2017.01.006_bib0055","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/BF00320164","article-title":"Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia","volume":"58","author":"Barosi","year":"1989","journal-title":"Blut"},{"issue":"6","key":"10.1016\/j.leukres.2017.01.006_bib0060","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2017.01.006_bib0065","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.leukres.2017.01.006_bib0070","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","article-title":"Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera","volume":"27","author":"Quintas-Cardama","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2017.01.006_bib0075","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00277-012-1560-9","article-title":"Pegylated interferon alpha2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation","volume":"92","author":"Dagorne","year":"2013","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2017.01.006_bib0080","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a","volume":"122","author":"Quintas-Cardama","year":"2013","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2017.01.006_bib0085","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2017.01.006_bib0090","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"97","author":"Gowin","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.leukres.2017.01.006_bib0095","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk","year":"2015","journal-title":"Thromb. Res."},{"key":"10.1016\/j.leukres.2017.01.006_bib0100","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","author":"Kiladjian","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2017.01.006_bib0105","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","article-title":"Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response","volume":"28","author":"Pizzi","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.leukres.2017.01.006_bib0110","first-page":"1","article-title":"Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera","author":"Utke Rank","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"23","key":"10.1016\/j.leukres.2017.01.006_bib0115","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2017.01.006_bib0120","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1182\/blood-2005-04-1520","article-title":"Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)","volume":"106","author":"Barosi","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2017.01.006_bib0125","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: international working group-Myeloproliferative neoplasms research and treatment (IWG-MRT) and european LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2017.01.006_bib0130","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","article-title":"Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis","volume":"116","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2017.01.006_bib0135","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.leukres.2017.01.006_bib0140","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2017.01.006_bib0145","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.leukres.2017.01.006_bib0150","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood.V126.23.60.60","article-title":"Efficacy and safety of pegylated interferon alpha-2a in patients with essential thrombocythemia and polycythemia vera: results after a median 7-year follow-up of a phase 2 study","volume":"126","author":"Masarova","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2017.01.006_bib0155","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V126.23.4064.4064","article-title":"Long-term interferon-\u03b1 treatment in essential thrombocythemia","volume":"126","author":"Stegelmann","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2017.01.006_bib0160","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.V126.23.1608.1608","article-title":"Long-term follow-up in interferon-alpha treated polycythemia vera patients \u2212 a single center analysis","volume":"126","author":"Jeryczynski","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2017.01.006_bib0165","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2017.01.006_bib0170","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s11899-014-0239-9","article-title":"Quality of life in MPN comes of age as a therapeutic target","volume":"9","author":"Scherber","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"33","key":"10.1016\/j.leukres.2017.01.006_bib0175","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2017.01.006_bib0180","article-title":"Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy","author":"Mesa","year":"2015","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2017.01.006_bib0185","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1056\/NEJMc1401255","article-title":"Interferon alfa therapy in CALR-mutated essential thrombocythemia","volume":"371","author":"Cassinat","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2017.01.006_bib0190","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","article-title":"Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report","volume":"117","author":"Silver","year":"2011","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2017.01.006_bib0195","first-page":"73","article-title":"Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera","volume":"3","author":"Bjorn","year":"2014","journal-title":"Leuk Res Rep"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617300085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T17:07:18Z","timestamp":1658336838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617300085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":39,"alternative-id":["S0145212617300085"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegylated interferon alpha \u2013 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}